Health insurance status and severe mpox disease outcomes among sexual minority men in NYC: a retrospective cohort study.

Publisher: BioMed Central Country of Publication: England NLM ID: 101190723 Publication Model: Electronic Cited Medium: Internet ISSN: 1741-7015 (Electronic) Linking ISSN: 17417015 NLM ISO Abbreviation: BMC Med Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2003-

Insurance Coverage*/statistics & numerical data ; Sexual and Gender Minorities*/statistics & numerical data ; Insurance, Health*/statistics & numerical data; New York City/epidemiology ; Humans ; Male ; Adult ; Retrospective Studies ; Middle Aged ; Severity of Illness Index ; Disease Outbreaks ; Young Adult

Background: The 2022-2023 global mpox outbreak predominantly affected sexual minority men, with notable racial/ethnic disparities in the USA. While the current literature has established the clinical predictors of severe mpox disease, little is known about the role of insurance status on clinical outcomes. We sought to characterize patients diagnosed with mpox in New York City (NYC) and examine associations between insurance status and mpox severity score (mpox-SS).
Methods: We included 143 patients aged 18 years and older between May 1, 2022, and December 31, 2023, with confirmed mpox identified through the electronic medical record. Demographics and clinical characteristics were summarized. Linear regression was performed to examine associations between insurance status and mpox-SS, controlling for race/ethnicity, high-risk condition (e.g., HIV with CD4 < 350 cells/mm³), prior vaccination with JYNNEOS or a smallpox vaccine, presence of a sexually transmitted infection (STI), and CDC Social Vulnerability Index.
Results: The mean age (SD) was 38.3 (10.2) years with 53 (37.1%) identifying as non-Hispanic White, 44 (30.8%) as Hispanic/Latino, and 30 (20.9%) as non-Hispanic Black. Over 90% were male sex at birth or identified as cisgender men and approximately 80% were sexual minority men. Ninety-six (67.1%) had private insurance, 6 (4.2%) Medicare, 35 (24.5%) Medicaid, and 4 were (2.8%) uninsured. Sixty-three (44.1%) had a confirmed HIV diagnosis, 25 (17.4%) patients had prior JYNNEOS vaccination, and 31 (21.7%) had a high-risk condition. Thirty-eight (26.6%) patients received tecovirimat; 21 (14.7%) patients were hospitalized, with 4 (2.8%) of those admitted to the ICU. The mean (SD) mpox-SS was 6.85 (3.36). In univariate analysis, lack of insurance or Medicaid status was associated significantly with more severe mpox-SS. Insurance status remained significant (p = 0.03) in multivariable models.
Conclusions: Being uninsured or on Medicaid was significantly associated with a higher mpox-SS in this diverse cohort of predominantly cisgender sexual minority men in NYC. High-risk status and lack of prior vaccination were associated with higher mpox-SS. Further studies are needed to assess the relationship between insurance, delays in access to care, or other socioeconomic inequities with severe mpox to understand the inequities beyond insurance access to prevent disparities in future outbreaks.
(© 2025. The Author(s).)

Declarations. Ethics approval and consent to participate: This study received approval from the New York University Institutional Review Board (IRB), i22-01375. Consent for publication: This study received a waiver of authorization and consent by the New York University IRB to conduct this study. Competing interests: The authors declare no competing interests.

Open Forum Infect Dis. 2023 Dec 05;10(12):ofad533. (PMID: 38058459)
BMJ Glob Health. 2025 Feb 03;10(2):. (PMID: 39900427)
N Engl J Med. 2023 Sep 21;389(12):1147-1148. (PMID: 37733313)
Lancet. 2023 Mar 18;401(10380):939-949. (PMID: 36828001)
Emerg Infect Dis. 2023 Nov;29(11):2353-2357. (PMID: 37796277)
J Gen Intern Med. 2009 Mar;24(3):415-20. (PMID: 19101775)
MMWR Morb Mortal Wkly Rep. 2023 Apr 28;72(17):471-472. (PMID: 37104293)
MMWR Morb Mortal Wkly Rep. 2022 Nov 04;71(44):1412-1417. (PMID: 36327164)
Lancet Infect Dis. 2024 Jan;24(1):57-64. (PMID: 37678309)
MMWR Morb Mortal Wkly Rep. 2023 May 19;72(20):553-558. (PMID: 37200229)
J Infect Dis. 2024 Mar 26;229(Supplement_2):S144-S155. (PMID: 37824825)
MMWR Morb Mortal Wkly Rep. 2023 Apr 14;72(15):404-410. (PMID: 37053126)
N Engl J Med. 2022 Aug 25;387(8):679-691. (PMID: 35866746)
MDM Policy Pract. 2018 Mar 26;3(1):2381468318760298. (PMID: 30288438)
MMWR Recomm Rep. 2014 Apr 11;63(RR-03):1-10. (PMID: 24717910)
J Infect Dis. 2024 Mar 26;229(Supplement_2):S234-S242. (PMID: 38001044)
Ther Adv Infect Dis. 2023 Aug 30;10:20499361231196683. (PMID: 37663111)
J Gen Intern Med. 2013 Sep;28(9):1136-42. (PMID: 23371419)
Public Health Rep. 2022 May-Jun;137(3):479-487. (PMID: 33789522)
Microorganisms. 2023 Nov 03;11(11):. (PMID: 38004713)
J Infect Dis. 2024 Mar 26;229(Supplement_2):S229-S233. (PMID: 37956401)
Lancet Infect Dis. 2023 Feb;23(2):196-206. (PMID: 36216018)
Am J Public Health. 2010 Mar;100(3):489-95. (PMID: 20075319)
Open Forum Infect Dis. 2023 Nov 02;10(11):ofad552. (PMID: 38023539)
Curr HIV/AIDS Rep. 2023 Aug;20(4):261-269. (PMID: 37178205)
AIDS. 2024 Jan 01;38(1):105-113. (PMID: 37812389)
Rev Med Virol. 2024 Jan;34(1):e2508. (PMID: 38282393)

P30 DA011041 United States DA NIDA NIH HHS; R01 MD013554 United States MD NIMHD NIH HHS; R01MD013554 United States NH NIH HHS; 5P30DA011041 United States NH NIH HHS

Keywords: Health insurance; Inequities; Mpox; Severe disease; Sociostructural factors

Date Created: 20250708 Date Completed: 20250709 Latest Revision: 20250712

20260130

PMC12239370

10.1186/s12916-025-04252-2

40629412